NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

The decision by NICE highlights the ongoing debate over cost-effectiveness versus potential benefits in dementia treatments.

• Donanemab, developed by Eli Lilly, has been shown to slow cognitive decline in Alzheimer's patients by targeting amyloid plaques in the brain.
• The National Institute for Health and Care Excellence (NICE) rejected the drug for NHS use, citing high costs relative to the benefits.
• Despite its rejection, Donanemab is licensed for use in the UK, allowing access through private clinics or clinical trials.
• The decision has sparked criticism from charities and experts, who argue that it overlooks the broader social and economic impacts of dementia.
• A new £20 million initiative, the Dementia Trials Accelerator, aims to increase clinical trial participation and fast-track new treatments.

21 Articles

The Independent The Telegraph The Telegraph The Guardian BBC Open Access Government Evening Standard The Independent Associated Press Evening Standard Stat News BBC Evening Standard The Guardian Evening Standard Evening Standard The Times Evening Standard The Telegraph The Telegraph